TSND-201

all catalysts(0)

nothing on the calendar yet

News(2)

• Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
  Eli Lilly’s $3.8 billion play for AtaiBeckley has fueled speculation that Big Pharma is ready to embrace psychedelics. But while the acquisition does validate the drug class, analysts say it is unl…
  biospace · 2mo ago
• Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics
  Eli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst caut…
  biospace · 2mo ago